Skip to content
OpenCapital
Get started

Immunovant, Inc. IMVT Research and development expenses

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0×0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept imvt:AccruedResearchAndDevelopmentExpenses.

The official record: Immunovant, Inc.’s 10-Q, filed February 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s research and development expenses.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunovant, Inc.'s research and development expenses?
Immunovant, Inc. (IMVT) reported research and development expenses of $38.67M in Q4 2025.
How has Immunovant, Inc.'s research and development expenses changed year-over-year?
Immunovant, Inc.'s research and development expenses increased by 8.7% year-over-year, from $35.58M to $38.67M.
What is the long-term trend for Immunovant, Inc.'s research and development expenses?
Over 4 years (2021 to 2025), Immunovant, Inc.'s research and development expenses has grown at a 33.9% compound annual growth rate (CAGR), from $10.15M to $32.62M.